11β-hydroxylase deficiency prevention

Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
11β-hydroxylase deficiency prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of 11β-hydroxylase deficiency prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on 11β-hydroxylase deficiency prevention
CDC on 11β-hydroxylase deficiency prevention
11β-hydroxylase deficiency prevention in the news
Blogs on 11β-hydroxylase deficiency prevention
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency
Risk calculators and risk factors for 11β-hydroxylase deficiency prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Prevention

• Prenatal diagnosis of 11-beta-hydroxylase deficiency is conducted to prevent complication of the disease in future life by prenatal dexamethasone treatment.